Trials / Completed
CompletedNCT06164431
Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273
Single-dose, Open-label, Randomized, Crossover Bioavailability Study of 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273 Under Fasted Condition in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to establish bioavailability of 2 treatments with ZSP1273: 200mg tablets and 200mg granules will be given to healthy Participants under fasting conditions. Bioavailability will be evaluated and verified on the basis of pharmacokinetic data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZSP1273 tablet | Participants receive ZSP1273 tablet orally. |
| DRUG | zsp1273 granules | Participants receive ZSP1273 granules orally. |
Timeline
- Start date
- 2023-11-23
- Primary completion
- 2023-12-15
- Completion
- 2023-12-22
- First posted
- 2023-12-11
- Last updated
- 2024-01-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06164431. Inclusion in this directory is not an endorsement.